Kottschade, L.A., Suman, V.J., Perez, D.G., McWilliams, R.R., Kaur, J.S., Amatruda 3rd, T.T., Geoffroy, F.J., Gross, H.M., Cohen, P.A., Jaslowski, A.J., et al. (2013) A Randomized Phase 2 Study of Temozolomide and Bevacizumab or Nab-Paclitaxel, Carboplatin and Bevacizumab in Patients with Unresectable Stage IV Melanoma: A North Central Cancer Treatment Group Study, N0775. Cancer, 119, 586-592.
http://dx.doi.org/10.1002/cncr.27760

has been cited by the following article:

• TITLE: Immunotherapy in Cancer Treatment

  AUTHORS: Aaron J. Smith, John Oertle, Dino Prato

  KEYWORDS: Immunotherapy, Cancer, T-cell, NK Cell, Dendrite, CIK, Nano Particles, Exosomes

  JOURNAL NAME: Open Journal of Medical Microbiology, Vol.4 No.3, September 11, 2014

  ABSTRACT: Various kinds of immunotherapy treatment for cancer are either available to the public or are in the process of clinical trials. Immunotherapy treatments have the potential to treat cancer with significantly less toxicity than chemotherapy and radiation treatments. An emphasis on cellular infusion as a method of either enhancing the immune system by creating an environment for sequestering the host immune system to attack cancer cells or more directly inserting cells to directly attack cancer cells will be provided in this review. Various forms of cancer vaccines are also discussed in this paper as an important aspect in immunotherapy. This review seeks to describe various methodologies associated with administering immunotherapy in the treatment of cancer.